**Specifications table**TableSubject area*Genetics*More specific subject area*Oncocytic tumors*Type of data*Table, text file*How data was acquired*Sanger sequencing of whole mitochondrial genomes*Data format*Analyzed*Experimental factors*Samples are parafin-bedded tissues*Experimental features*The whole mitochondrial genomes from the tumor tissues were sequenced, the variations were identified by comparing sequences with the revised Cambridge sequence (rCRS) (GenBank number*[NC_012920](ncbi-n:NC_012920){#ir0005}*); the predictions for pathogenicity of mtDNA variants were established according to the Mitimpact 2 program.*Data source location*Wenzhou, China*Data accessibility*The data are available with this article*

**Value of the data**•The data identified inherited mtDNA variants associated with patients with oncocytic tumors.•The data showed some identified mtDNA variants could have functional consequences.•The data might help to detect new genetic predisposition markers for oncocytomas.

1. Data {#s0005}
=======

The data were presented as tables, where positions, detail changes ([Table 1](#t0005){ref-type="table"}), and the implications were provided ([Table 2](#t0010){ref-type="table"}).Table 1MtDNA variants not defining haplogroups of our patients.Table 1LocusMtDNA variantsAmino acid changePolyPhen 2 scoreAnnotation statusTVm.1623G\>AtRNA valine--NovelRNR2m.1719G\>A16 s RNA--KNPND1m.3398 T\>CMet→Tyr0.02cardiomyopathy-associatedND2m.4935 A\>GThr→Ala0KNPm.5178 C\>ALeu→Met0.9Longevity;AMS protection;blood iron metabolismCO1m.6221 T\>CN--KNPm.6267 G\>AAla→Thr0.01Prostate Cancerm.6371 C\>TN--KNPm.6680 T\>CN--KNPCO2m.8239 C\>AIle→Met0.29Novelm.8240 T\>APhe→Ile0.99Novelm.8241 T\>APhe→Tyr0.98NovelCO3m.9510 T\>CTyr →His1Novelm.9698 T\>CN--KNPTRm.10410 T\>CtRNA arginine--KNPND4Lm.10490 T\>CN--KNPm.10530 G\>AVal→Met0.02KVPND4m.11531 G\>AAla→Thr0.18KNPm.11719 G\>AN--KNPm.11968 A\>TN--KNPm.12131 T\>CSer→Pro0.05KNPm.12811 T\>CTyr→His0.01Possible LHON factorm.13674 T\>CN--KNPm.13590 G\>AN--KNPm.13934 C\>TThr→Met0.08KNPm.13966 A\>GThr→Ala0.01KNPND5m.14097 C\>TN--KNPND6m.14180 T\>CTyr→Cys0.96KNPCYBm.14766 C\>TThr→Ile0.01KNPm.15746 A\>GIle→Val0breast tumorD-Loopm.193 A\>G----KNPm.298 C\>T----KNPm.310 T\>C----KNPm.310 ins C----Melanoma patientsm.310 ins CC----KNPm.316 G\>C----KNPm.316 GC----Novelm.318 ins CC----Novelm.523 del A----KNPm.524 del C----KNPm.16278 C\>T----KNPm.16327 C\>T----KNPm.16360 C\>T----KNPm.16497 A\>G----KNPm.16519 T\>C----KNPm.16526 G\>A----KNP[^1][^2]Table 2The pathogenic prediction of 4 novel missense mtDNA variants identified in this study.Table 2**Indexm.8239 C\>Am.8240 T\>Am.8241 T\>Am.9510 T\>CAA position**I218MF219IF219YY102H**PolyPhen2**BenignProbably damagingProbably damagingProbably damaging**SIFT**NeutralNeutralNeutralNeutral**FatHmmW**NeutralDeleteriousNeutralNeutral**PROVEAN**NeutralDeleteriousDeleteriousDeleterious**Mutation Assessor**Neutral impactHigh impactMedium impactMedium impact**EFIN SP**NeutralDamagingDamagingDamaging**EFIN HD**NeutralNeutralNeutralDamaging**CADD**DeleteriousDeleteriousDeleteriousDeleterious**PANTHER**DiseaseDiseaseNeutralNeutral**PhD-SNP**NeutralDiseaseDiseaseDisease**SNAP**NeutralDiseaseDiseaseDisease**Meta-SNP**NeutralDiseaseDiseaseDisease**CAROL**NeutralDeleteriousDeleteriousDeleterious**Condel**NeutralNeutralDeleteriousNeutral**COVEC WMV**NeutralDeleteriousDeleteriousDeleterious**MtoolBox**NeutralDeleteriousDeleteriousDeleterious**PolyPhen2 transf**Medium impactLow impactLow impactLow impact**SIFT transf**Medium impactMedium impactHigh impactMedium impact**Mutation Assessor transf**Low impactHigh impactMedium impactMedium impact**MutationTaster**PolymorphismPolymorphismDisease causingPolymorphism

2. Experimental design, materials and methods {#s0010}
=============================================

We collected 32 cases of the parafin-bedded tissues with oncocytic tumor and matched adjacent normal tissues, mtDNA were amplified by PCR using 24 previously reported pairs of mtDNA primers to cover the whole mtDNA genome as our previous work [@bib1]. MtDNA variants were yielded by comparing sequencing results of the complete mitochondrial genome with the revised Cambridge sequence (rCRS) (GenBank number [NC_012920](ncbi-n:NC_012920){#ir0010}). The heteroplasmy were defined if a double peaks of two residues were verified at the same position in the electro-chromatograms. Pathogenic prediction were analyzed using PolyPhen2 (<http://genetics.bwh.harvard.edu/pph2/>) [@bib2] and MitImpact 2 [@bib3].
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[^1]: The DNA variants detected both in oncocytic tumors and adjacent normal subjects.

[^2]: N, no amino acid change; --, Not applicable; KNP, Known sequence nucleotide polymorphism; Annotation status in Mitomap, the mtDNA variants associated with diseases or being a somatic events in other disease summarised in Mitomap database.
